# MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

> **NCT05286788** · PHASE2 · RECRUITING · sponsor: **Nationwide Children's Hospital** · enrollment: 38 (estimated)

## Conditions studied

- Adamantinous Craniopharyngioma
- Recurrent Adamantinomatous Craniopharyngioma

## Interventions

- **DRUG:** Binimetinib Oral Tablet [Mektovi]

## Key facts

- **NCT ID:** NCT05286788
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-10
- **Primary completion:** 2027-04-10
- **Final completion:** 2027-04-10
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286788, "MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05286788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*